Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with...
Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria
About this item
Full title
Author / Creator
Kulasekararaj, Austin , Brodsky, Robert , Schrezenmeier, Hubert , Griffin, Morag , Röth, Alexander , Piatek, Caroline , Ogawa, Masayo , Yu, Ji , Patel, Ami S. , Patel, Yogesh , Notaro, Rosario , Usuki, Kensuke , Kulagin, Alexander , Gualandro, Sandra , Füreder, Wolfgang , Peffault de Latour, Regis , Szer, Jeff and Lee, Jong Wook
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Ravulizumab is a second-generation complement component 5 (C5) inhibitor (C5i) approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) following positive results from two pivotal trials in patients with PNH originally naive to C5i treatment and eculizumab-experienced patients with PNH. In both trials, after the 26week primary evalua...
Alternative Titles
Full title
Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11868214
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11868214
Other Identifiers
ISSN
0939-5555,1432-0584
E-ISSN
1432-0584
DOI
10.1007/s00277-025-06193-5
